Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Ampio Pharmaceuticals (NYSE:AMPEGet Rating) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Down 7.3 %

Ampio Pharmaceuticals stock opened at $0.30 on Wednesday. Ampio Pharmaceuticals has a one year low of $0.20 and a one year high of $9.71. The stock has a fifty day moving average of $0.27. The company has a market capitalization of $4.59 million, a price-to-earnings ratio of -0.16 and a beta of 1.60.

Ampio Pharmaceuticals Company Profile

(Get Rating)

Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.

Further Reading

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.